Drug intelligence / Profile preview

ARC101

Development stage: Phase 1
Lead developer: Third Arc Bio
Modality: T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

ARC101 is a bispecific antibody T cell engager developed by Third Arc Bio for the treatment of solid tumors expressing Claudin 6 (CLDN6). It is designed to have high specificity for CLDN6, avoiding off-target binding to other Claudin family proteins. The drug works by engaging T cells via CD3 and directing them to kill CLDN6-positive tumor cells, resulting in potent cytotoxicity. ARC101 has a long half-life and optimal biophysical properties. It is currently being evaluated in a phase 1 clinical trial as monotherapy in patients with locally advanced or metastatic solid tumors expressing CLDN6.

Targets

CLDN6 (Claudin-6)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on ARC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC101.